Tinnitus Suppression for Cochlear Implant Recipients

Overview

Tinnitus is the perception of sound in the absence of an external sound. Prevalence in the general population is 10 to 15%, with tinnitus severely impacting quality of life in 1-2 percent of the population. Tinnitus therapy is based on counselling, cognitive and behavioural therapies in combination with sound therapies which mostly rely on masking. For cochlear implant candidates, the ability to use hearing aids and maskers is limited by the degree of their hearing loss. Reports of tinnitus prevalence in this group range from 67 to 100% with a mean of 80%. In cochlear implant (CI) recipients, tinnitus suppression primarily occurs during active use of the cochlear implant system. In some CI recipients residual inhibition of tinnitus occurs when the implant is switched off. While the benefits of CI implantation on tinnitus are well documented, there is a group of recipients where tinnitus remains a concern in the implanted ear post-operatively. The primary aim of this study is to investigate the benefits of using tinnitus masking via a CI sound processor that optimises tinnitus suppression with minimal annoyance to the user. Furthermore a questionnaire will be employed to capture the prevalence, degree and nature of tinnitus in recipients.

Full Title of Study: “Evaluation of Tinnitus Suppression for Cochlear Implant Recipients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2018

Interventions

  • Device: Tinnitus masking
    • Tinnitus masking via CI system

Arms, Groups and Cohorts

  • Experimental: Cochlear Implant Recipients

Clinical Trial Outcome Measures

Primary Measures

  • Tinnitus Severity Questionnaire
    • Time Frame: Testing over 6 months
    • Tinnitus severity questionnaire using Visual Analog Scale
  • Word recognition scores in quiet
    • Time Frame: Testing over 6 months
    • Monosyllabic word scores in quiet
  • Speech recognition scores in noise
    • Time Frame: Testing over 6 months
    • Sentence recognition scores in noise

Secondary Measures

  • Degree of handicap as a result of tinnitus
    • Time Frame: Testing over 6 months
    • Tinnitus Handicap Questionnaire used to capture degree of overall handicap as a result of tinnitus

Participating in This Clinical Trial

Inclusion Criteria

1. 18 years of age or older 2. Freedom or CI500 series implant 3. At least 3 months experience with the cochlear implant 4. Native speaker in the language used to assess speech perception performance 5. Willingness to participate in and to comply with all requirements of the protocol 6. Self-reported tinnitus in the implanted ear 7. Reside local to investigational site Exclusion Criteria:

1. Signs of retrocochlear or central origin to hearing impairment as confirmed by medical examination and test including MRI 2. Additional handicaps that would prevent participations in evaluations 3. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The Hearing Cooperative Research Centre
  • Collaborator
    • Royal Victoria Eye and Ear Hospital
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.